Catalyst

Slingshot members are tracking this event:

Gelesis (PTCHF) Expects Data Readout in First Half of 2017 of 3 Month Proof-of-Concept Trial Evaluating Gelesis200 in Glycemic Control and Weight Loss in Prediabetic & Type 2 Diabetic Patients

Source Link:
http://www.gelesis.com/press-releases/05032016.php

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
PTCHF
100%
Gelesis
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters (STAGE)
https://clinicaltria...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 31, 2016
Occurred Source:
http://gelesis.com/pdf/Urban-STAGE-TOS-2016-handout-Final.pdf
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Data Readout, 3 Month, Proof-of-concept Trial, Gelesis200, Glycemic Control, Weight Loss, Prediabetic, Type 2 Diabetic
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.